The Role of Hemolysis

What is hemolysis?

Hemolysis is a medical way of saying “destruction of red blood cells (RBCs).” Hemolysis is measured by LDH (lactate dehydrogenase, an enzyme found in red blood cells) and elevated levels of LDH are an indicator of excessive hemolysis.1 In healthy people, low levels of hemolysis are constant and naturally occurring. However, in people with PNH, there is excessive hemolysis resulting from a missing protective surface protein on some or all RBCs. This excessive hemolysis releases the toxic contents of RBCs into the bloodstream, which, over time, can cause many of the symptoms associated with PNH and harm important organs in your body.

If you have PNH, hemolysis is always taking place — whether you feel OK or whether you’re having a flare-up (paroxysm), such as during times of stress or infection.1-4 Excessive and continual hemolysis is the main cause of major health problems in PNH.

Why is hemolysis important?

When blood cells are destroyed, their toxic contents are released into the bloodstream and can build up, causing health problems that can occur suddenly at any time.3,4 These problems can include kidney failure and serious blood clots, which may cause damage to important organs like your liver, brain, and lungs.1

Hemolysis also affects the way you feel. Many people with PNH report that the unpredictability of the frequency and severity of their symptoms impairs their quality of life. Physicians believe reducing chronic hemolysis is an important goal in PNH treatment.





IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).

Please see full prescribing information for SOLIRIS, including boxed WARNING regarding serious meningitis.


References: 1. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243. 2. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-1258. 3. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137:181-192. 4. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653-1662.